YAKUGAKU ZASSHI
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama 
Read more
17,073 registered articles
(updated on April 24, 2019)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
0.293
2017 IMPACT FACTOR
JOURNALS PEER REVIEWED FREE ACCESS ADVANCE PUBLICATION
Featured article
Volume 139 (2019) Issue 4 Pages 629-633
Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy Read more
Editor’s picks

The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for treatment of non-Hodgkin lymphoma. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, therefore, preventing FN is important for successful treatment. The authors compared the efficacy of pegfilgrastim with that of filgrastim in patients receiving DA-EPOCH-R and showed that pegfilgrastim seems to be better than filgrastim for the primary prophylaxis, maintaining chemotherapy dosage, and reducing hospital duration. 

View the past featured articles
View all articles in Current issue
Most viewed articles Mar.2019
Share this page
Select past volume & issue
feedback
Top